Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral S-ketamine add-on for treatment-resistant major depressive disorder
NL-OMON46103Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Oral S-ketamine augmentation with Placebo augmentation (2 arms). Primary endpoints: Change in depressive symptom severity, Response rate and 1 more. Started Feb 2017; status: active, not recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON46103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46103.